Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.

Liang YinKai-Cai LiuWei-Fu LvShao-Bao XuDong LuChun-Ze ZhouDe-Lei ChengZong-Gen GaoChang-Sheng ShiMing-Xue Su

Published in: Drug design, development and therapy (2022)

Tumor hypervascularity and development of RCCEP were favorable predictive factors for the combination treatment of TACE and carrelizumab, with both of which the patients survived longest and might be the potential candidates.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
signaling pathway
prognostic factors
combination therapy
patient reported outcomes
smoking cessation